Top

Published in:

01-08-2018 | Lymphoma (DO Persky, Section Editor)

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence

Authors: Thomas A. Ollila, MD, Adam J. Olszewski, MD

Published in: Current Treatment Options in Oncology | Issue 8/2018

Opinion statement

Diffuse large B cell lymphoma (DLBCL) arises from extranodal organs in about 30% of cases. Its prognosis and risk of recurrence in the central nervous system (CNS) vary according to the primary site of origin. Recent studies begin to clarify these differences using molecular classification. Testicular, breast, and uterine DLBCL (as well as possibly primary cutaneous DLBCL, leg-type) share a high prevalence of the non-germinal center B cell (non-GCB) phenotype and the MYD88/CD79B-mutated (MCD) genotype. These biologic features, which resemble primary CNS lymphoma, may underlie their stage-independent propensity for CNS involvement. Management of these lymphomas should involve CNS prophylaxis, preferably using systemic high-dose methotrexate to prevent intraparenchymal recurrence. Involvement of the kidneys, adrenal glands, ovary, bone marrow, lung, or pleura usually indicates disseminated disease, conferring worse prognosis. Involvement of these sites is often associated with high CNS-International Prognostic Index (IPI), concurrent MYC and BCL2 or BCL6 rearrangements, or intravascular lymphoma—risk factors warranting CNS prophylaxis. In contrast, craniofacial, thyroid, localized bone, or gastric lymphomas have a variable prevalence of the non-GCB phenotype and lack MYD88 mutations. Their outcomes with standard immunochemotherapy are excellent, and the risk of CNS recurrence is low. We recommend individualized consideration of CNS prophylaxis based on the CNS-IPI score and anatomical proximity in cases of epidural, orbital, or skull involvement. Rituximab-containing immunochemotherapy is a standard approach for all extranodal DLBCLs. Surgery is no longer required for any primary site, but routine consolidative radiation therapy is recommended for testicular lymphoma. Radiation therapy also appears to be associated with better progression-free survival in primary bone DLBCL. Future studies should better distinguish primary from secondary sites of extranodal involvement, and investigate the association of newly identified genotypes with the risk of CNS or systemic recurrence.

Swerdlow SH, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. ed. World Health Organization classification of tumours. Lyon: International Agency for Research on Cancer; 2017.

Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89(3):310–4. https://doi.org/10.1002/ajh.23638.PubMedCrossRef

El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET/CT and rituximab era: a Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90(11):1041–6. https://doi.org/10.1002/ajh.24169.PubMedCrossRef

Hui D, Proctor B, Donaldson J, Shenkier T, Hoskins P, Klasa R, et al. Prognostic implications of extranodal involvement in patients with diffuse large B-cell lymphoma treated with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone. Leuk Lymphoma. 2010;51(9):1658–67. https://doi.org/10.3109/10428194.2010.504872. PubMedCrossRef

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23(18):4117–26. https://doi.org/10.1200/JCO.2005.09.131.PubMedCrossRef

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105–16. https://doi.org/10.1016/S1470-2045(08)70002-0.PubMedCrossRef

Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817–26. https://doi.org/10.1016/S0140-6736(13)60313-X.PubMedCrossRef

Lamy T, Damaj G, Soubeyran P, Gyan E, Cartron G, Bouabdallah K, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131(2):174–81. https://doi.org/10.1182/blood-2017-07-793984.PubMedCrossRef

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123(6):837–42. https://doi.org/10.1182/blood-2013-09-524108.PubMedPubMedCentralCrossRef

10.

Olszewski AJ, Winer ES, Castillo JJ. Improved survival with rituximab-based chemoimmunotherapy in older patients with extranodal diffuse large B-cell lymphoma. Leuk Res. 2014;38(8):866–73. https://doi.org/10.1016/j.leukres.2014.04.009.PubMedCrossRef

11.

Ferreri AJ. Risk of CNS dissemination in extranodal lymphomas. Lancet Oncol. 2014;15(4):e159–69. https://doi.org/10.1016/S1470-2045(13)70568-0.PubMedCrossRef

12.

Olszewski AJ, Winer ES, Castillo JJ. Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base. Cancer Causes Control. 2015;26(8):1163–72. https://doi.org/10.1007/s10552-015-0610-8.PubMedCrossRef

13.

Montalban C, Diaz-Lopez A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2-microglobulin yields a more accurate GELTAMO-IPI. Br J Haematol. 2017;176(6):918–28. https://doi.org/10.1111/bjh.14489.PubMedCrossRef

14.

Takahashi H, Tomita N, Yokoyama M, Tsunoda S, Yano T, Murayama K, et al. Prognostic impact of extranodal involvement in diffuse large B-cell lymphoma in the rituximab era. Cancer. 2012;118(17):4166–72. https://doi.org/10.1002/cncr.27381.PubMedCrossRef

15.

Lu CS, Chen JH, Huang TC, Wu YY, Chang PY, Dai MS, et al. Diffuse large B-cell lymphoma: sites of extranodal involvement are a stronger prognostic indicator than number of extranodal sites in the rituximab era. Leuk Lymphoma. 2015;56(7):2047–55. https://doi.org/10.3109/10428194.2014.982636.PubMedCrossRef

16.

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503–11. https://doi.org/10.1038/35000501.PubMedCrossRef

17.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937–47. https://doi.org/10.1056/NEJMoa012914.PubMedCrossRef

18.

Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hanel M, et al. The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas. Blood. 2014;124(5):720–8. https://doi.org/10.1182/blood-2013-10-535021.PubMedCrossRef

19.

Lee GW, Go SI, Kim SH, Hong J, Kim YR, Oh S, et al. Clinical outcome and prognosis of patients with primary sinonasal tract diffuse large B-cell lymphoma treated with rituximab-cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy: a study by the Consortium for Improving Survival of Lymphoma. Leuk Lymphoma. 2015;56(4):1020–6. https://doi.org/10.3109/10428194.2014.946027.PubMedCrossRef

20.

Carreras J, Kikuti YY, Bea S, Miyaoka M, Hiraiwa S, Ikoma H, et al. Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (DLBCL) reveals gain at 1q31 and RGS1 encoding protein; high RGS1 immunohistochemical expression associates with poor overall survival in DLBCL not otherwise specified (NOS). Histopathology. 2017;70(4):595–621. https://doi.org/10.1111/his.13106. PubMedCrossRef

21.

Watanabe N, Noh JY, Narimatsu H, Takeuchi K, Yamaguchi T, Kameyama K, et al. Clinicopathological features of 171 cases of primary thyroid lymphoma: a long-term study involving 24553 patients with Hashimoto’s disease. Br J Haematol. 2011;153(2):236–43. https://doi.org/10.1111/j.1365-2141.2011.08606.x.PubMedCrossRef

22.

Knief J, Gebauer N, Bernard V, Schemme J, Reddemann K, Gebauer J, et al. Oncogenic mutations and chromosomal aberrations in primary extranodal diffuse large B-cell lymphomas of the thyroid—a study of 21 cases. J Clin Endocrinol Metab. 2015;100(2):754–62. https://doi.org/10.1210/jc.2014-3250.PubMedCrossRef

23.

Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179(5):739–47. https://doi.org/10.1111/bjh.14951.PubMedCrossRef

24.

Kawajiri A, Maruyama D, Maeshima AM, Nomoto J, Makita S, Kitahara H, et al. Impact of the double expression of MYC and BCL2 on outcomes of localized primary gastric diffuse large B-cell lymphoma patients in the rituximab era. Blood Cancer J. 2016;6(9):e477. https://doi.org/10.1038/bcj.2016.88.PubMedPubMedCentralCrossRef

25.

Sohn BS, Kim SM, Yoon DH, Kim S, Lee DH, Kim JH, et al. The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Ann Hematol. 2012;91(11):1731–9. https://doi.org/10.1007/s00277-012-1512-4.PubMedCrossRef

26.

Kuo SH, Yeh KH, Chen LT, Lin CW, Hsu PN, Hsu C, et al. Helicobacter pylori-related diffuse large B-cell lymphoma of the stomach: a distinct entity with lower aggressiveness and higher chemosensitivity. Blood Cancer J. 2014;4:e220. https://doi.org/10.1038/bcj.2014.40.PubMedPubMedCentralCrossRef

27.

Frick M, Bettstetter M, Bertz S, Schwarz-Furlan S, Hartmann A, Richter T, et al. Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL. Leuk Lymphoma. 2018;59(5):1260–3. https://doi.org/10.1080/10428194.2017.1370546.PubMedCrossRef

28.

Nagakita K, Takata K, Taniguchi K, Miyata-Takata T, Sato Y, Tari A, et al. Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P. Pathol Int. 2016;66(8):444–52. https://doi.org/10.1111/pin.12439.PubMedCrossRef

29.

Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002–7. https://doi.org/10.3324/haematol.2011.041277.PubMedPubMedCentralCrossRef

30.

Lehners N, Kramer I, Schwarzbich MA, Ho AD, Witzens-Harig M. Analysis of clinical characteristics and outcome of patients with previously untreated diffuse large B-cell lymphoma and renal involvement in the rituximab era. Leuk Lymphoma. 2016;57(11):2619–25. https://doi.org/10.3109/10428194.2016.1157869.PubMedCrossRef

31.

Kridel R, Telio D, Villa D, Sehn LH, Gerrie AS, Shenkier T, et al. Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era. Br J Haematol. 2017;176(2):210–21. https://doi.org/10.1111/bjh.14392.PubMedCrossRef

32.

• Deng L, Xu-Monette ZY, Loghavi S, Manyam GC, Xia Y, Visco C, et al. Primary testicular diffuse large B-cell lymphoma displays distinct clinical and biological features for treatment failure in rituximab era: a report from the International PTL Consortium. Leukemia. 2016;30(2):361–72. https://doi.org/10.1038/leu.2015.237. A multi-institutional observational series describing therapy and outcomes of primary testicular lymphoma. It suggests a benefit of prophylactic intrathecal therapy and radiation therapy, which were associated with lower risk of recurrence.PubMedCrossRef

33.

Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. Br J Haematol. 2014;165(3):358–63. https://doi.org/10.1111/bjh.12753.PubMedPubMedCentralCrossRef

34.

Yhim HY, Kim JS, Kang HJ, Kim SJ, Kim WS, Choi CW, et al. Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer. 2012;131(1):235–43. https://doi.org/10.1002/ijc.26352.PubMedCrossRef

35.

Aviles A, Neri N, Nambo MJ. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol. 2012;35(2):126–9. https://doi.org/10.1097/COC.0b013e318209aa12.PubMedCrossRef

36.

Cao XX, Li J, Cai H, Zhang W, Duan MH, Zhou DB. Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations. Ann Hematol. 2017;96(11):1867–71. https://doi.org/10.1007/s00277-017-3094-7.PubMedCrossRef

37.

Taniguchi K, Takata K, Chuang SS, Miyata-Takata T, Sato Y, Satou A, et al. Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma. Am J Surg Pathol. 2016;40(3):324–34. https://doi.org/10.1097/PAS.0000000000000592.PubMedCrossRef

38.

• El-Galaly TC, Cheah CY, Hutchings M, Mikhaeel NG, Savage KJ, Sehn LH, et al. Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement. Br J Haematol. 2016;175(5):876–83. https://doi.org/10.1111/bjh.14325. An intrenational observational study demonstrating high risk of CNS recurrence in DLBCL involving the uterus.PubMedCrossRef

39.

Pham-Ledard A, Beylot-Barry M, Barbe C, Leduc M, Petrella T, Vergier B, et al. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type. JAMA Dermatol. 2014;150(11):1173–9. https://doi.org/10.1001/jamadermatol.2014.821.PubMedCrossRef

40.

Pham-Ledard A, Prochazkova-Carlotti M, Deveza M, Laforet MP, Beylot-Barry M, Vergier B, et al. Molecular analysis of immunoglobulin variable genes supports a germinal center experienced normal counterpart in primary cutaneous diffuse large B-cell lymphoma, leg-type. J Dermatol Sci. 2017;88(2):238–46. https://doi.org/10.1016/j.jdermsci.2017.07.008.PubMedCrossRef

41.

Wu H, Zhang L, Shao H, Sokol L, Sotomayor E, Letson D, et al. Prognostic significance of soft tissue extension, international prognostic index, and multifocality in primary bone lymphoma: a single institutional experience. Br J Haematol. 2014;166(1):60–8. https://doi.org/10.1111/bjh.12841.PubMedCrossRef

42.

Tao R, Allen PK, Rodriguez A, Shihadeh F, Pinnix CC, Arzu I, et al. Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphoma. Int J Radiat Oncol Biol Phys. 2015;92(1):122–9. https://doi.org/10.1016/j.ijrobp.2015.01.014.PubMedCrossRef

43.

Held G, Zeynalova S, Murawski N, Ziepert M, Kempf B, Viardot A, et al. Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvement. J Clin Oncol. 2013;31(32):4115–22. https://doi.org/10.1200/JCO.2012.48.0467.PubMedCrossRef

44.

Li X, Xu-Monette ZY, Yi S, Dabaja BS, Manyam GC, Westin J, et al. Primary bone lymphoma exhibits a favorable prognosis and distinct gene expression signatures resembling diffuse large B-cell lymphoma derived from centrocytes in the germinal center. Am J Surg Pathol. 2017;41(10):1309–21. https://doi.org/10.1097/PAS.0000000000000923.PubMedCrossRef

45.

Pilorge S, Harel S, Ribrag V, Larousserie F, Willems L, Franchi P, et al. Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies. Leuk Lymphoma. 2016;57(12):2820–6. https://doi.org/10.1080/10428194.2016.1177180.PubMedCrossRef

46.

• Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378(15):1396–407. https://doi.org/10.1056/NEJMoa1801445. Large translational study identifying DLBCL genotype categories associated with disparate survival outcomes. It identfied the MYD88/CD79B-mutated genotype particularly prevalent in certain extranodal lymphomas.PubMedCrossRefPubMedCentral

47.

Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3452–9. https://doi.org/10.1200/JCO.2011.41.0985.PubMedPubMedCentralCrossRef

48.

Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166(6):891–901. https://doi.org/10.1111/bjh.12982.PubMedCrossRef

49.

Petrich AM, Gandhi M, Jovanovic B, Castillo JJ, Rajguru S, Yang DT, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124(15):2354–61. https://doi.org/10.1182/blood-2014-05-578963.PubMedCrossRef

50.

Niitsu N, Okamoto M, Miura I, Hirano M. Clinical features and prognosis of de novo diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC translocations. Leukemia. 2009;23(4):777–83. https://doi.org/10.1038/leu.2008.344.PubMedCrossRef

51.

Savage KJ, Johnson NA, Ben-Neriah S, Connors JM, Sehn LH, Farinha P, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533–7. https://doi.org/10.1182/blood-2009-05-220095.PubMedCrossRef

52.

Tomita N, Tokunaka M, Nakamura N, Takeuchi K, Koike J, Motomura S, et al. Clinicopathological features of lymphoma/leukemia patients carrying both BCL2 and MYC translocations. Haematologica. 2009;94(7):935–43. https://doi.org/10.3324/haematol.2008.005355.PubMedPubMedCentralCrossRef

53.

Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121(20):4021–31; quiz 250. https://doi.org/10.1182/blood-2012-10-460063.PubMedPubMedCentralCrossRef

54.

Savage KJ, Slack GW, Mottok A, Sehn LH, Villa D, Kansara R, et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood. 2016;127(18):2182–8. https://doi.org/10.1182/blood-2015-10-676700.PubMedCrossRef

55.

Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121(12):2253–63. https://doi.org/10.1182/blood-2012-06-435842.PubMedCrossRef

56.

Staiger AM, Ziepert M, Horn H, Scott DW, Barth TFE, Bernd HW, et al. Clinical impact of the cell-of-origin classification and the MYC/ BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin’s Lymphoma Study Group. J Clin Oncol. 2017;35(22):2515–26. https://doi.org/10.1200/JCO.2016.70.3660.PubMedCrossRef

57.

Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30(28):3460–7. https://doi.org/10.1200/JCO.2011.41.4342.PubMedCrossRef

58.

Xu-Monette ZY, Wu L, Visco C, Tai YC, Tzankov A, Liu WM, et al. Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2012;120(19):3986–96. https://doi.org/10.1182/blood-2012-05-433334.PubMedPubMedCentralCrossRef

59.

Wang XJ, Medeiros LJ, Bueso-Ramos CE, Tang G, Wang S, Oki Y, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30(2):194–203. https://doi.org/10.1038/modpathol.2016.178.PubMedCrossRef

60.

Karube K, Enjuanes A, Dlouhy I, Jares P, Martin-Garcia D, Nadeu F, et al. Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia. 2018;32(3):675–84. https://doi.org/10.1038/leu.2017.251.PubMedCrossRef

61.

Reddy A, Zhang J, Davis NS, Moffitt AB, Love CL, Waldrop A, et al. Genetic and functional drivers of diffuse large B cell lymphoma. Cell. 2017;171(2):481–94 e15. https://doi.org/10.1016/j.cell.2017.09.027.PubMedCrossRefPubMedCentral

62.

Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood. 2009;113(17):3896–902. https://doi.org/10.1182/blood-2008-10-182253.PubMedCrossRef

63.

• Gleeson M, Counsell N, Cunningham D, Chadwick N, Lawrie A, Hawkes EA, et al. Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial. Ann Oncol. 2017;28(10):2511–6. https://doi.org/10.1093/annonc/mdx353. Re-analysis of a randomized trial, identifying risk factors for CNS recurrence and its association with certain extranodal sites of involvement. It also confirms that parenchymal brain recurrences predominate in the RCHOP era.PubMedCrossRefPubMedCentral

64.

El-Galaly TC, Villa D, Michaelsen TY, Hutchings M, Mikhaeel NG, Savage KJ, et al. The number of extranodal sites assessed by PET/CT scan is a powerful predictor of CNS relapse for patients with diffuse large B-cell lymphoma: an international multicenter study of 1532 patients treated with chemoimmunotherapy. Eur J Cancer. 2017;75:195–203. https://doi.org/10.1016/j.ejca.2016.12.029.PubMedCrossRef

65.

van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood. 1998;91(4):1178–84.PubMed

66.

Bos GM, van Putten WL, van der Holt B, van den Bent M, Verdonck LF, Hagenbeek A. For which patients with aggressive non-Hodgkin’s lymphoma is prophylaxis for central nervous system disease mandatory? Dutch HOVON Group. Ann Oncol. 1998;9(2):191–4.PubMedCrossRef

67.

Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H. Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol. 2002;13(7):1099–107.PubMedCrossRef

68.

•• Schmitz N, Zeynalova S, Nickelsen M, Kansara R, Villa D, Sehn LH, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016;34(26):3150–6. https://doi.org/10.1200/JCO.2015.65.6520. Large observational study describing development of the CNS-IPI in a cohort of clinical trial participants. The index was then validated in an independent population-based cohort from BCCA.PubMedCrossRef

69.

Kansara R, Villa D, Gerrie AS, Klasa R, Shenkier T, Scott DW, et al. Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model. Br J Haematol. 2017;179(3):508–10. https://doi.org/10.1111/bjh.14229.PubMedCrossRef

70.

Chin CK, Cheah CY. How I treat patients with aggressive lymphoma at high risk of CNS relapse. Blood. 2017;130(7):867–74. https://doi.org/10.1182/blood-2017-03-737460.PubMedCrossRef

71.

McMillan A, Ardeshna KM, Cwynarski K, Lyttelton M, McKay P, Montoto S, et al. Guideline on the prevention of secondary central nervous system lymphoma: British Committee for Standards in Haematology. Br J Haematol. 2013;163(2):168–81. https://doi.org/10.1111/bjh.12509. PubMedCrossRef

72.

Penalver FJ, Sancho JM, de la Fuente A, Olave MT, Martin A, Panizo C, et al. Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO). Haematologica. 2017;102(2):235–45. https://doi.org/10.3324/haematol.2016.149120.PubMedPubMedCentralCrossRef

73.

Malecek MK, Petrich AM, Rozell S, Chu B, Trifilio S, Galanina N, et al. Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. Am J Hematol. 2017;92(11):1156–62. https://doi.org/10.1002/ajh.24864.PubMedCrossRef

74.

Thakral B, Medeiros LJ, Desai P, Lin P, Yin CC, Tang G, et al. Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017;98(4):415–21. https://doi.org/10.1111/ejh.12847.PubMedCrossRef

75.

Alinari L, Gru A, Quinion C, Huang Y, Lozanski A, Lozanski G, et al. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort. Am J Hematol. 2016;91(4):395–9. https://doi.org/10.1002/ajh.24299.PubMedPubMedCentralCrossRef

76.

Xu-Monette ZY, Tu M, Jabbar KJ, Cao X, Tzankov A, Visco C, et al. Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in western countries. Oncotarget. 2015;6(8):5615–33. https://doi.org/10.18632/oncotarget.3479. PubMedPubMedCentralCrossRef

77.

Miyazaki K, Yamaguchi M, Suzuki R, Kobayashi Y, Maeshima AM, Niitsu N, et al. CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab. Ann Oncol. 2011;22(7):1601–7. https://doi.org/10.1093/annonc/mdq627.PubMedCrossRef

78.

Camilleri-Broet S, Criniere E, Broet P, Delwail V, Mokhtari K, Moreau A, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases. Blood. 2006;107(1):190–6. https://doi.org/10.1182/blood-2005-03-1024.PubMedCrossRef

79.

Gonzalez-Aguilar A, Idbaih A, Boisselier B, Habbita N, Rossetto M, Laurenge A, et al. Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas. Clin Cancer Res. 2012;18(19):5203–11. https://doi.org/10.1158/1078-0432.CCR-12-0845.PubMedCrossRef

80.

•• Chapuy B, Roemer MG, Stewart C, Tan Y, Abo RP, Zhang L, et al. Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood. 2016;127(7):869–81. https://doi.org/10.1182/blood-2015-10-673236. Translational study identifying common genomic features of primary CNS and testicular lymphoma. These features include prevalent MYD88 and CD79B mutations, as well as copy number alterations involving the PD-L1 / PD-L2 genes.PubMedPubMedCentralCrossRef

81.

Braggio E, Van Wier S, Ojha J, McPhail E, Asmann YW, Egan J, et al. Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas. Clin Cancer Res. 2015;21(17):3986–94. https://doi.org/10.1158/1078-0432.CCR-14-2116.PubMedPubMedCentralCrossRef

82.

Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968–73. https://doi.org/10.1158/1078-0432.CCR-09-0108.PubMedCrossRef

83.

Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, et al. Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma. Carcinogenesis. 2017;38(8):812–20. https://doi.org/10.1093/carcin/bgx061.PubMedPubMedCentralCrossRef

84.

Lemma SA, Pasanen AK, Haapasaari KM, Sippola A, Sormunen R, Soini Y, et al. Similar chemokine receptor profiles in lymphomas with central nervous system involvement—possible biomarkers for patient selection for central nervous system prophylaxis, a retrospective study. Eur J Haematol. 2016;96(5):492–501. https://doi.org/10.1111/ejh.12626.PubMedCrossRef

85.

Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin’s lymphoma: a 20-year follow-up analysis of SWOG 8516—the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114–9. https://doi.org/10.1200/JCO.2008.16.8021.PubMedPubMedCentralCrossRef

86.

Kumar A, Vanderplas A, LaCasce AS, Rodriguez MA, Crosby AL, Lepisto E, et al. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer. 2012;118(11):2944–51. https://doi.org/10.1002/cncr.26588.PubMedCrossRef

87.

Zhang J, Chen B, Xu X. Impact of rituximab on incidence of and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: a systematic review and meta-analysis. Leuk Lymphoma. 2014;55(3):509–14. https://doi.org/10.3109/10428194.2013.811239.PubMedCrossRef

88.

Zahid MF, Khan N, Hashmi SK, Kizilbash SH, Barta SK. Central nervous system prophylaxis in diffuse large B-cell lymphoma. Eur J Haematol. 2016;97(2):108–20. https://doi.org/10.1111/ejh.12763.PubMedCrossRef

89.

Abramson JS, Hellmann M, Barnes JA, Hammerman P, Toomey C, Takvorian T, et al. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma. Cancer. 2010;116(18):4283–90. https://doi.org/10.1002/cncr.25278.PubMedCrossRef

90.

Ferreri AJ, Bruno-Ventre M, Donadoni G, Ponzoni M, Citterio G, Foppoli M, et al. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era. Br J Haematol. 2015;168(5):654–62. https://doi.org/10.1111/bjh.13194.PubMedCrossRef

91.

Holte H, Leppa S, Bjorkholm M, Fluge O, Jyrkkio S, Delabie J, et al. Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study. Ann Oncol. 2013;24(5):1385–92. https://doi.org/10.1093/annonc/mds621.PubMedCrossRef

92.

Recher C, Coiffier B, Haioun C, Molina TJ, Ferme C, Casasnovas O, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet. 2011;378(9806):1858–67. https://doi.org/10.1016/S0140-6736(11)61040-4.PubMedCrossRef

93.

Laskin JJ, Savage KJ, Voss N, Gascoyne RD, Connors JM. Primary paranasal sinus lymphoma: natural history and improved outcome with central nervous system chemoprophylaxis. Leuk Lymphoma. 2005;46(12):1721–7. https://doi.org/10.1080/17402520500182345.PubMedCrossRef

94.

Moller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation—a population-based study of 1575 cases. Br J Haematol. 2004;124(2):151–9. https://doi.org/10.1046/j.1365-2141.2003.04749.x.PubMedCrossRef

95.

Ho JC, Dabaja BS, Milgrom SA, Smith GL, Reddy JP, Mazloom A, et al. Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. Leuk Lymphoma. 2017;58(12):2833–44. https://doi.org/10.1080/10428194.2017.1312381. PubMedPubMedCentralCrossRef

96.

de Leval L, Bonnet C, Copie-Bergman C, Seidel L, Baia M, Briere J, et al. Diffuse large B-cell lymphoma of Waldeyer’s ring has distinct clinicopathologic features: a GELA study. Ann Oncol. 2012;23(12):3143–51. https://doi.org/10.1093/annonc/mds150.PubMedCrossRef

97.

Stein SA, Wartofsky L. Primary thyroid lymphoma: a clinical review. J Clin Endocrinol Metab. 2013;98(8):3131–8. https://doi.org/10.1210/jc.2013-1428.PubMedCrossRef

98.

Onal C, Li YX, Miller RC, Poortmans P, Constantinou N, Weber DC, et al. Treatment results and prognostic factors in primary thyroid lymphoma patients: a rare cancer network study. Ann Oncol. 2011;22(1):156–64. https://doi.org/10.1093/annonc/mdq310.PubMedCrossRef

99.

Cardenas-Garcia J, Talwar A, Shah R, Fein A. Update in primary pulmonary lymphomas. Curr Opin Pulm Med. 2015;21(4):333–7. https://doi.org/10.1097/MCP.0000000000000180.PubMedCrossRef

100.

Steidl C, Gascoyne RD. The molecular pathogenesis of primary mediastinal large B-cell lymphoma. Blood. 2011;118(10):2659–69. https://doi.org/10.1182/blood-2011-05-326538.PubMedCrossRef

101.

Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–16. https://doi.org/10.1056/NEJMoa1214561.PubMedPubMedCentralCrossRef

102.

Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180(4):534–44. https://doi.org/10.1111/bjh.15051.PubMedCrossRef

103.

Kuo SH, Yeh KH, Wu MS, Lin CW, Hsu PN, Wang HP, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H pylori-positive gastric diffuse large B-cell lymphomas. Blood. 2012;119(21):4838–44; quiz 5057. https://doi.org/10.1182/blood-2012-01-404194.PubMedCrossRef

104.

Ferreri AJ, Govi S, Raderer M, Mule A, Andriani A, Caracciolo D, et al. Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial. Blood. 2012;120(18):3858–60. https://doi.org/10.1182/blood-2012-06-438424.PubMedCrossRef

105.

Liu Y, Yu K, Li M, Zeng K, Wei J, Li X, et al. EZH2 overexpression in primary gastrointestinal diffuse large B-cell lymphoma and its association with the clinicopathological features. Hum Pathol. 2017;64:213–21. https://doi.org/10.1016/j.humpath.2017.04.011.PubMedCrossRef

106.

Bronowicki JP, Bineau C, Feugier P, Hermine O, Brousse N, Oberti F, et al. Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients. Hepatology. 2003;37(4):781–7. https://doi.org/10.1053/jhep.2003.50121.PubMedCrossRef

107.

Peng Y, Qing AC, Cai J, Yue C, French SW, Qing X. Lymphoma of the liver: clinicopathological features of 19 patients. Exp Mol Pathol. 2016;100(2):276–80. https://doi.org/10.1016/j.yexmp.2016.02.001.PubMedCrossRef

108.

Page RD, Romaguera JE, Osborne B, Medeiros LJ, Rodriguez J, North L, et al. Primary hepatic lymphoma: favorable outcome after combination chemotherapy. Cancer. 2001;92(8):2023–9.PubMedCrossRef

109.

Rashidi A, Fisher SI. Primary adrenal lymphoma: a systematic review. Ann Hematol. 2013;92(12):1583–93. https://doi.org/10.1007/s00277-013-1812-3.PubMedCrossRef

110.

Kim YR, Kim JS, Min YH, Hyunyoon D, Shin HJ, Mun YC, et al. Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL). J Hematol Oncol. 2012;5:49. https://doi.org/10.1186/1756-8722-5-49.PubMedPubMedCentralCrossRef

111.

Hussain S, Hallam S, Beltran L, Haroon A, Majumdar K, Shamash J, et al. Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis. Br J Haematol. 2017; https://doi.org/10.1111/bjh.14715.

112.

Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, et al. High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma. Blood. 2018; https://doi.org/10.1182/blood-2017-12-822817.

113.

Kraan W, van Keimpema M, Horlings HM, Schilder-Tol EJ, Oud ME, Noorduyn LA, et al. High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma. Leukemia. 2014;28(3):719–20. https://doi.org/10.1038/leu.2013.348.PubMedCrossRef

114.

Oishi N, Kondo T, Nakazawa T, Mochizuki K, Tanioka F, Oyama T, et al. High prevalence of the MYD88 mutation in testicular lymphoma: immunohistochemical and genetic analyses. Pathol Int. 2015;65(10):528–35. https://doi.org/10.1111/pin.12336.PubMedCrossRef

115.

Vitolo U, Chiappella A, Ferreri AJ, Martelli M, Baldi I, Balzarotti M, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766–72. https://doi.org/10.1200/JCO.2010.31.4187.PubMedCrossRef

116.

Ollila TA, Olszewski AJ. Radiation therapy in primary testicular lymphoma (PTL): does practice match the standard of care? ASCO Annual Meeting. 2018. Abs. 7544.

117.

Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008;19(2):233–41. https://doi.org/10.1093/annonc/mdm471.PubMedCrossRef

118.

Thomas A, Link BK, Altekruse S, Romitti PA, Schroeder MC. Primary breast lymphoma in the United States: 1975–2013. J Natl Cancer Inst. 2017;109(6) https://doi.org/10.1093/jnci/djw294.

119.

Cao XX, Li J, Zhang W, Duan MH, Shen T, Zhou DB. Patients with primary diffuse large B-cell lymphoma of female genital tract have high risk of central nervous system relapse. Ann Hematol. 2014;93(6):1001–5. https://doi.org/10.1007/s00277-013-2003-y.PubMedCrossRef

120.

Wilcox RA. Cutaneous B-cell lymphomas: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(10):1052–5. https://doi.org/10.1002/ajh.24462.PubMedCrossRef

121.

Grange F, Joly P, Barbe C, Bagot M, Dalle S, Ingen-Housz-Oro S, et al. Improvement of survival in patients with primary cutaneous diffuse large B-cell lymphoma, leg type, in France. JAMA Dermatol. 2014;150(5):535–41. https://doi.org/10.1001/jamadermatol.2013.7452.PubMedCrossRef

122.

Pham-Ledard A, Prochazkova-Carlotti M, Andrique L, Cappellen D, Vergier B, Martinez F, et al. Multiple genetic alterations in primary cutaneous large B-cell lymphoma, leg type support a common lymphomagenesis with activated B-cell-like diffuse large B-cell lymphoma. Mod Pathol. 2014;27(3):402–11. https://doi.org/10.1038/modpathol.2013.156.PubMedCrossRef

123.

Hoefnagel JJ, Dijkman R, Basso K, Jansen PM, Hallermann C, Willemze R, et al. Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling. Blood. 2005;105(9):3671–8. https://doi.org/10.1182/blood-2004-04-1594.PubMedCrossRef

124.

Gardette E, Maraval A, Brunet-Possenti F, Quereux G, Beltraminelli H, Templier I, et al. Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. J Eur Acad Dermatol Venereol. 2017;31(11):e498–501. https://doi.org/10.1111/jdv.14358. PubMedCrossRef

125.

Bekkenk MW, Postma TJ, Meijer CJ, Willemze R. Frequency of central nervous system involvement in primary cutaneous B-cell lymphoma. Cancer. 2000;89(4):913–9.PubMedCrossRef

126.

Bruno Ventre M, Ferreri AJ, Gospodarowicz M, Govi S, Messina C, Porter D, et al. Clinical features, management, and prognosis of an international series of 161 patients with limited-stage diffuse large B-cell lymphoma of the bone (the IELSG-14 study). Oncologist. 2014;19(3):291–8. https://doi.org/10.1634/theoncologist.2013-0249.PubMedPubMedCentralCrossRef

127.

Messina C, Ferreri AJ, Govi S, Bruno-Ventre M, Gracia Medina EA, Porter D, et al. Clinical features, management and prognosis of multifocal primary bone lymphoma: a retrospective study of the international extranodal lymphoma study group (the IELSG 14 study). Br J Haematol. 2014;164(6):834–40. https://doi.org/10.1111/bjh.12714.PubMedCrossRef

128.

Xu Y, Li J, Ouyang J, Li J, Xu J, Zhang Q, et al. Prognostic relevance of protein expression, clinical factors, and MYD88 mutation in primary bone lymphoma. Oncotarget. 2017;8(39):65609–19. https://doi.org/10.18632/oncotarget.19936. PubMedPubMedCentralCrossRef

Title: Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence
Authors: Thomas A. Ollila, MD
Adam J. Olszewski, MD
Publication date: 01-08-2018
Publisher: Springer US
Published in: Current Treatment Options in Oncology / Issue 8/2018
Print ISSN: 1527-2729
Electronic ISSN: 1534-6277
DOI: https://doi.org/10.1007/s11864-018-0555-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Opinion statement

Please log in to get access to this content

Other articles of this Issue 8/2018

Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer

Diagnosis and Management of Acral Lentiginous Melanoma

The Role of Advanced Brain Tumor Imaging in the Care of Patients with Central Nervous System Malignancies

Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine

Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas

Head and Neck Cancer Survivorship Care: A Review of the Current Guidelines and Remaining Unmet Needs

Keynote webinar | Spotlight on antibody–drug conjugates in cancer